Infliximab as disease-modifying therapy

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 3, 2003, Pages 233-237

  D'Haens, Geert R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Infliximab; Monoclonal antibodies; Tumour necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRALGIA; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INFLAMMATORY CELL; JOINT STIFFNESS; PRIORITY JOURNAL; RASH; REVIEW; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037342090     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200303000-00004     Document Type: Review

References (31)

1. Beutler BA. The role of tumour necrosis factor in health and disease. J Rheumatol 1999; 26 (suppl 57):16-21.
2. Barbara JA, Van Ostade X, Lopez A. Tumour necrosis factor alpha (TNF-α): the good, the bad and the potentially very effective. Immunol Cell Biol 1996; 75:434-443.
3. Riddle NH. Tumour necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr Opin Immunol 1992; 4:327-332.
4. Plevy SE, Targan SR, Deem RL, Toyoda H. Increased mucosal TNF-α levels and numbers of TNF-α producing cells are unique to Crohn's disease mucosal inflammation. Gastroenterology 1995; 106:A754.
5. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumour necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455-1466.
6. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89-91.
7. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34:1705-1709.
8. Lukacs NW, Chensue SW, Strieter R, Warmington K, Kunkel SL. Inflammatory granuloma formation is mediated by TNF-alpha inducible intercellular adhesion molecule-1. J Immunol 1994; 152:5883-5889.
9. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human anti-TNF-antibody. Mol Immunol 1993; 30:1443-1453.
10. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo. Cytokine 1995; 7:15-25.
11. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-monoclonal antibody cA2 binds recombinant transmembrane TNF and activates immune effector functions. Cytokine 1995; 7:251-259.
12. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-211. Important work illustrating the mechanism of action of infliximab and explaining why it might be superior to other anti-TNF antibodies.
13. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035. Pivotal trial demonstrating the potent efficacy of infliximab in active Crohn's disease.
14. McCabe RP, Woody J, van Deventer SJH, Targan SR, Mayer L, van Hogezand R, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996; 110:A962.
15. D'Haens G, van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-1034. This trial shows consistent endoscopic healing with infliximab in parallel with clinical improvement and accompanied by disappearance of inflammatory cells from the inflamed mucosa.
16. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumour necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-28.
17. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: the first 100 patients. Am J Gastroenterol 2001; 96;722-729.
18. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95:3089-3194.
19. Rutgeerts P, D'Haens G, Targan S, van Deventer SH, Present DH, Mayer L. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-769. This trial not only showed that repeated infusions of infliximab continue to be effective and, more importantly, that the incidence of adverse events did not increase with repeated use.
20. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Lancet 2002; 359:1541-1549. This trial is, so far, the largest controlled trial in Crohn's disease. Due to its meticulous but complex design, many questions were addressed at the same time. Results show that both systematic and 'on demand' retreatment with infliximab are safe and effective.
21. D'Haens GR, Noman M, Baert F, Hiele M, Van Assche G, Daperno M, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse [Abstract]. Gastroenterology 2002; 122:A100.
22. Present DH,. Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405. Largest ever trial in fistulizing Crohn's disease. Although the efficacy was better than has ever been shown with other therapies, the duration of response was disappointingly short, in spite of an induction regimen of three infusions.
23. Sands B, Van Deventer S, Bernstein C, Kamm M, Rachmilewitz D, Chey W, et al. Long-term treatment of fistulizing Crohn's disease: response to infliximab in the Accent II trial through 54 weeks [Abstract]. Gastroenterology 2002; 122:A81.
24. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45:39-45.
25. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Ailment Pharmacol Ther 2001; 15:463-473.
26. Noman M, Baert F, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Post infusion infliximab levels determine duration of response in Crohn's disease and are directly related to infusion reactions [Abstract]. Gastroenterology 2002; 122:A100.
27. Alsahli M, Jeen YT, Peppercorn M, Michetti P, Farrell RJ. A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy [Abstract]. Gastroenterology 2002; 122:A100.
28. Hanauer SB, Rutgeerts PJ, D'Haens GR, Targan SR, Kam L, Present DH, et al. Delayed hypersensitivity to infliximab (Remicade) infusion after a 2-4 year interval without treatment [Abstract]. Gastroenterology 1999; 116:G3174.
29. Keane J, Gershon S, Wise RP, Mirabile-Levens E. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
30. Mow WS, Abreu MT, Papadakis KA, Targan SR, Vasiliauskas EA. High incidence of anergy limits the usefulness of PPD screening for tuberculosis prior to Remicade in inflammatory bowel disease [Abstract]. Gastroenterology 2002; 122:A100.
31. Toy LS, Abittan C, Kornbluth A, Scherl EJ, Greenstein AJ, Agus S, et al. Complete bowel obstruction following initial response to infliximab therapy: a series of a newly described complication. Gastroenterology 2000; 118:A569.